Cytostatic drug treatment causes seeding of gene promoter methylation

[1]  R. Glasspool,et al.  Epigenetics as a mechanism driving polygenic clinical drug resistance , 2006, British Journal of Cancer.

[2]  K. Shimizu,et al.  Aberrant methylation patterns of the Rassf1a gene in rat lung adenocarcinomas induced by N‐nitrosobis(2‐hydroxypropyl)amine , 2006, Molecular carcinogenesis.

[3]  B. Hales,et al.  Epigenetic programming in the preimplantation rat embryo is disrupted by chronic paternal cyclophosphamide exposure , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[4]  T. Ushijima,et al.  Detection and interpretation of altered methylation patterns in cancer cells , 2005, Nature Reviews Cancer.

[5]  A. Kaneda,et al.  Decreased fidelity in replicating CpG methylation patterns in cancer cells. , 2005, Cancer research.

[6]  Robert Brown,et al.  Epigenetic silencing mediated by CpG island methylation: potential as a therapeutic target and as a biomarker. , 2004, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[7]  Robert Brown,et al.  The Acquisition of hMLH1 Methylation in Plasma DNA after Chemotherapy Predicts Poor Survival for Ovarian Cancer Patients , 2004, Clinical Cancer Research.

[8]  S. Clark,et al.  Transcriptional Gene Silencing Promotes DNA Hypermethylation through a Sequential Change in Chromatin Modifications in Cancer Cells , 2004, Cancer Research.

[9]  W. Bodmer,et al.  Loss of CDX1 expression in colorectal carcinoma: promoter methylation, mutation, and loss of heterozygosity analyses of 37 cell lines. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[10]  Thomas P. Yang,et al.  Role of the Promoter in Maintaining Transcriptionally Active Chromatin Structure and DNA Methylation Patterns In Vivo , 2003, Molecular and Cellular Biology.

[11]  Robert Brown,et al.  Aberrant DNA Methylation in Ovarian Cancer , 2003 .

[12]  Max Costa,et al.  Epigenetics and the Environment , 2003, Annals of the New York Academy of Sciences.

[13]  H. Sano,et al.  Periodic DNA Methylation in Maize Nucleosomes and Demethylation by Environmental Stress* , 2002, The Journal of Biological Chemistry.

[14]  T. Tomasi,et al.  DNA Alkylating Agents Alleviate Silencing of Class II Transactivator Gene Expression in L1210 Lymphoma Cells1 , 2002, The Journal of Immunology.

[15]  S. Clark,et al.  Hypermethylation trigger of the glutathione-S-transferase gene (GSTP1) in prostate cancer cells , 2002, Oncogene.

[16]  E. Richards,et al.  Epigenetic variation in Arabidopsis disease resistance. , 2002, Genes & development.

[17]  A. Tates,et al.  Validation of the human T-lymphocyte cloning assay--ring test report from the EU concerted action on HPRT mutation (EUCAHM). , 1999, Mutation research.

[18]  J. Nyce,et al.  Drug-induced DNA hypermethylation: a potential mediator of acquired drug resistance during cancer chemotherapy. , 1997, Mutation research.

[19]  B. Vogelstein,et al.  Increased mutation rate at the hprt locus accompanies microsatellite instability in colon cancer. , 1995, Oncogene.

[20]  M. Gottesman.  How cancer cells evade chemotherapy: sixteenth Richard and Hinda Rosenthal Foundation Award Lecture. , 1993, Cancer research.

[21]  R. Holliday,et al.  DNA methylation and epigenetic inheritance. , 2002, Methods.

[22]  C. Caskey,et al.  HPRT: gene structure, expression, and mutation. , 1985, Annual review of genetics.

[23]  E. Witebsky.  Histocompatibility Testing, 1967 , 1969 .